China
Africa
Explore chapters and articles related to this topic
Omadacycline
Published in M. Lindsay Grayson, Sara E. Cosgrove, Suzanne M. Crowe, M. Lindsay Grayson, William Hope, James S. McCarthy, John Mills, Johan W. Mouton, David L. Paterson, Kucers’ The Use of Antibiotics, 2017
Omadacycline is not (yet) available for clinical use and is currently being evaluated in phase III clinical trials for the treatment of complicated skin and skin structure infections and community-acquired pneumonia. Formulations used in phase III clinical trials include 100 mg i.v. once daily, and 200 and 300 mg orally once daily.
Omadacycline in treating community-based infections: a review and expert perspective
Published in Expert Review of Anti-infective Therapy, 2023
George Sakoulas, Michael Nowak, Matthew Geriak
O’Riordan W, Green S, Overcash JS et al. Omadacycline for acute bacterial skin and skin-structure infections. N Engl J Med 2019; 380: 528–38.O’Riordan W, Cardenas C, Shin E et al. Once-daily oral omadacycline versus twice-daily oral linezolid for acute bacterial skin and skin structure infections (OASIS-2): a phase 3, double-blind, multicentre, randomised, controlled, non-inferiority trial. Lancet Infect Dis 2019; 19: 1080–90.Stets R, Popescu M, Gonong JR, Mitha I, Nseir W, Madej A, Kirsch C, Das AF, Garrity-Ryan L, Steenbergen JN, Manley A, Eckburg PB, Tzanis E, McGovern PC, Loh E. Omadacycline for community-acquired bacterial pneumonia. N Engl J Med 2019; 380 (6): 517–527. PMID: 30,726,692.
Emerging antibiotics for community-acquired pneumonia
Published in Expert Opinion on Emerging Drugs, 2019
Adamantia Liapikou, Catia Cilloniz, Andrea Palomeque, Toni Torres
Solithromycin benefits from having multiple binding sites in the 50S ribosome, making it more potent than other macrolides. Its oral formulation appears to be clinically effective, well tolerated, and to be suitable for once daily dosing over 5 days. We anticipate that its development will be pursued to treat infections in children and pregnancy given its desirable antibacterial activities and safety profile in preclinical studies. Omadacycline (a newly approved cycline) offers a single-agent parenteral or oral alternative to traditional empirical therapy in bacterial CAP. Additionally, it is significantly more active than doxycycline or minocycline against Enterobacteriaceae and A. baumannii, and meets the FDA criterion for susceptibility of K. pneumoniae. Unfortunately, patients with severe CAP (Fine class V) or those who presented in septic shock were excluded from the RCTs of solithromycin and omadacycline, so we lack clinical data for their use in those patients.
Novel developments in the treatment of acute bacterial skin and skin structure infections
Published in Expert Opinion on Pharmacotherapy, 2019
Rupal K. Jaffa, Kelly E. Pillinger, Danya Roshdy, Jacqueline A. Isip, Timothy R. Pasquale
Although derived from the tetracycline class, omadacycline is a novel aminomethylcycline, which inhibits protein synthesis by binding the 30S bacterial ribosome [49]. Due to the novel structure, omadacycline is able to overcome the most common types of resistance, including efflux pumps and ribosomal protection, that cause resistance in older tetracyclines such as doxycycline and minocycline [49,50]. Approved by the FDA in October 2018 for the treatment of ABSSSI and community acquired pneumonia, omadacycline has broad spectrum coverage including Gram-positives, Gram-negatives, anaerobes, and atypical organisms [49]. Of particular importance for ABSSSI, omadacycline has good activity against S. aureus (including MRSA), Streptococcus pyogenes, Streptococcus anginosus group, and Enterobacteriaceae [51].